BMPR2 and pulmonary arterial hypertension: Accumulated evidence indicates that PAH patients carrying a BMPR2 mutation develop PAH approximately 10 years earlier than non-carriers, with a more severe hemodynamic compromise at diagnosis, and are less likely to respond to acute vasodilator testing [4-6].